Cipla files ANDA to treat asthma

Cipla Limited today informed the bourses about the submission of an abbreviated new drug application (ANDA) to USFDA.

Cipla has filed ANDA for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) to United States Food & Drug Administration (USFDA).

The above-mentioned product is the generic version of GSK’s Advair Diskus. This is specifically used to treat asthma and chronic bronchitis.

As per the data of IQVIA (IMS Health), US sales of Advair Diskus is nearly $2.9 billion for the 12-month period ending March 2020.

Recently, the company has also announced the successful completion of its phase-3 clinical end-point study for the product in the first attempt.

Cipla Limited is a pharmaceutical company, having strategic business units, which includes active pharmaceutical ingredients (APIs), respiratory as well as Cipla Global Access.

Today, the stock of Cipla opened at Rs 570.45 and made jumped by three per cent and made an intraday high of Rs 589 on BSE.